Clinical Trials
임상시험 트래커
국내사는 전체 임상 이력, 글로벌 메이저는 진행 중 파이프라인을 추적합니다. ClinicalTrials.gov API v2에서 6시간 주기로 수집합니다.
기업
60 results (top 60)
- 1/2상모집 예정· Hormone Receptor Positive호르몬 수용체 양성, HER2-저/초저발현 절제 불가능 또는 전이성 유방암 환자에서 파트리투맙 데룩스테칸(HER3-DXd)과 트라스투주맙 데룩스테칸(T-DXd) 병용 투여 연구
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중· Malignant Neoplasm재발 또는 난치성 고형종양 소아 참가자를 대상으로 한 이피나타맙 데럭스테칸 임상시험(MK-9999-01D/LIGHTBEAM-U01)
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Malignant Neoplasm일본 소아 고형암·림프종 및 성인 머클세포암종 환자를 대상으로 하는 펨브롤리주맙 연구 (MK-3475-G21/KEYNOTE-G21)
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
리드: 머크(MSD)
- 1/2상모집 중· Lymphoma, Non-Hodgkin비호지킨림프종 환자에서 MK-1045의 임상시험(MK-1045-008)
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
리드: 머크(MSD)
- 1/2상모집 중· Lung Neoplasm Malignant비소세포폐암 치료를 위한 MK-1084와 다른 치료법의 임상 연구(MK-3475-01F)
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
리드: 머크(MSD)
- 1/2상모집 예정· Recurrent Respiratory Papillomatosis (RRP)재발성 호흡기 유두종증이 있는 성인의 수술 간격에 대한 가다실9 백신 부스터 주사의 효과
Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*
협력: 머크(MSD)
- 1/2상모집 중· Locally Advanced or Metastatic Solid Tumors국소진행성 또는 전이성 고형종양에서 BC3195와 펨브롤리주맙 병용 투여 연구
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Oesophageal Squamous Cell Carcinoma진행 식도암 환자에서 이피나타맙 데룩스테칸 임상시험
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
리드: 머크(MSD)
- 1/2상모집 중· Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaA Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
협력: 머크(MSD)
- 1/2상모집 중· Small Cell Lung Cancer Extensive StageA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
리드: 머크(MSD)
- 1/2상모집 중· Bladder CancerA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
리드: 머크(MSD)
- 1/2상모집 중· Solid TumorsABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Esophageal Squamous Cell CarcinomaSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
리드: 머크(MSD)
- 1/2상모집 중· Cervical AdenocarcinomaExternal Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
협력: 머크(MSD)
- 1/2상모집 중· Castration-Resistant Prostatic CancerA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
리드: 머크(MSD)
- 1/2상모집 중· Malignant NeoplasmA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Ovarian Cancer RecurrentA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
리드: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorsPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Bladder CancerEnfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorsA Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
리드: 머크(MSD)
- 1/2상모집 중· Non-Muscle Invasive Bladder CancerA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Melanoma MetastaticDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
협력: 머크(MSD)
- 1/2상모집 중· Gastrointestinal CancerStudy of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Non-small Cell Lung CancerA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· MSI-H/dMMR Gastroesophageal-junction CancerA Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
협력: 머크(MSD)
- 1/2상모집 중· B-cell Acute Lymphoblastic LeukemiaSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Gastroesophageal JunctionSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
리드: 머크(MSD)
- 1/2상모집 중· Extensive Stage-small Cell Lung CancerA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Urothelial CarcinomaA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
리드: 머크(MSD)
- 1/2상모집 중· Colorectal CancerA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
리드: 머크(MSD)
- 1/2상모집 중· Prostatic Neoplasms, Castration-ResistantSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
리드: 머크(MSD)
- 1/2상모집 중· Recurrent or Metastatic Solid TumorsA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Bladder CancerA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
리드: 머크(MSD) · 협력: 모더나
- 1/2상모집 중단 (진행 중)· Glioblastoma MultiformeT Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
협력: 머크(MSD)
- 1/2상모집 중· Metastatic Breast CancerA Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중· HPV Positive Oropharyngeal Squamous Cell CarcinomaSafety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Solid TumorsBI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Urothelial CarcinomaA Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
리드: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorPembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중· Esophageal Squamous Cell CarcinomaA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
리드: 머크(MSD)
- 1/2상모집 중· Solid Tumor, AdultA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
협력: 머크(MSD)
- 1/2상모집 중· Gastric or Gastroesophageal Junction AdenocarcinomaSpevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
협력: 머크(MSD)
- 1/2상모집 중· Solid TumorStudy of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Esophageal CancerOral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상조기 종료· Advanced or Metastatic Solid TumorsA Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· MelanomaA Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
협력: 머크(MSD)
- 1/2상모집 중· Advanced CancerHighly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Renal Cell CarcinomaA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
리드: 머크(MSD)
- 1/2상모집 중· Advanced/Metastatic Solid TumorsADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Solid TumorsS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.